PHARMATHER

3D Printed Personalized Medicine

pharmather.com

Corporate Presentation · November 2026

CSE: PHRM | OTCQB: PHRRF

Forward-Looking Statements

This presentation contains "forward-looking information" within the meaning of applicable Canadian securities legislation with respect to PharmaTher Holdings Ltd. (the "Company"). All information other than statements of historical fact is forward-looking information, including statements regarding: the Company's corporate strategy and business model; the M3DICINES™ platform and brand; the M3DICINES™ National Network Program, including the enrollment of Network Partners, the terms on which CraftMake™ systems are placed in the network and the expectation that nodes will generate product, licensing, white-label, CDMO, consumables, service, research and government revenue; the commercial plan for CraftMake™, including initial orders, the target of up to 50 placements over the next 12 months, the estimated number of potential placement sites and the expectation that placements will generate recurring revenue; the development, launch timing and commercialization of the Company's 503A products, including Rx wellness, peptide and longevity products, and the potential compounding of additional peptides following FDA rulemaking; the Company's FDA rare pediatric disease program for 3D-printed creatine monohydrate in GAMT deficiency, including the FDA's review of, and decisions on, the Company's Orphan Drug and Rare Pediatric Disease Designation applications, a pre-IND meeting, clinical development, the timing of an NDA submission, potential approval, orphan exclusivity and potential eligibility for, award of and sale value of a priority review voucher; the evaluation and potential development of products for ultra-rare diseases; plans to supply psychedelic medicines for clinical trials and special access programs; plans to identify and reintroduce discontinued medicines and to make medicines in short supply; the planned National Emergency Preparedness Node Network, its demonstration and potential readiness contracts; partnering opportunities, including CDMO services, white-label products, formulation licensing and research collaborations; the timing and amount of payments from the sale of the Company's ketamine ANDA; the potential licensing, sale, partnering or spin-out of strategic assets; anticipated market growth; and upcoming milestones and catalysts. Forward-looking information is based on management's current expectations, estimates and assumptions, including that Craft Health, PD Labs and the Company's GMP manufacturing and other partners will perform as expected, that Network Partners will join the network on acceptable terms, that the Company will maintain its exclusive distribution rights and obtain financing on acceptable terms, and that regulatory frameworks will develop as expected. It is subject to known and unknown risks, uncertainties and other factors that may cause actual results to differ materially from those expressed or implied, including the risks that Network Partners may not join the network or placements may not generate the expected revenue, that expanding the network requires capital that may not be recovered, that compounding is subject to substance eligibility under Section 503A and state pharmacy laws, that there is no finalized FDA framework for distributed pharmaceutical manufacturing, that government funding and procurement are uncertain, that the FDA may not grant either designation or may require more evidence than anticipated, that clinical development may not succeed or may take longer or cost more than expected, that regulatory approval may not be obtained, and that a priority review voucher may not be awarded or sold on attractive terms, including because the rare pediatric disease priority review voucher program is currently authorized only through September 30, 2029. No assurance can be given that any of the events anticipated will occur or, if they do, what benefits the Company will derive from them. Product candidates described in this presentation are at a development stage; they are investigational and have not been approved by the FDA, Health Canada or any other regulator. Compounded drugs are not FDA-approved, and certain peptides, including BPC-157, may not be compounded unless and until the FDA completes the applicable rulemaking. Ketamine, psilocybin and MDMA are controlled substances. Program cost and timing figures are internal estimates. Voucher sale prices are taken from public disclosures by the companies involved and have not been independently verified. Market, industry and third-party data have not been independently verified by the Company. This presentation does not constitute an offer to sell or a solicitation of an offer to buy any securities of the Company in any jurisdiction. Readers are cautioned not to place undue reliance on forward-looking information and should review the Company's public filings on SEDAR+ (www.sedarplus.ca) for a full discussion of risk factors. The Company undertakes no obligation to update forward-looking information except as required by law.

CraftMake™, CraftControl™ and CraftBlends™ are trademarks of Craft Health. M3DICINES™ is a trademark of PharmaTher Holdings Ltd. KetaMist® is a trademark of its owner.

Pharmaceutical 3D Printing for Personalized Medicine

M3DICINES™ Platform


CraftMake™ 3D printer · Novel formulations

PERSONALIZ3D™ Peptides

Gummy and Tablet (BPC-157 and KPV) · NAD+ Gummy

Partnering

In-house 3D printing · Development · Alliances · Licensing



CraftMake™ by Craft Health

±1%

dose precision

No heat


no UV · room temperature

GMP-ready

enclosed · dual printheads

DOSAGE FORMS


Gummies


Layered gummies


Multi-layer tablets


Capsules


Pellets

Our Mission

Medicine is made for everyone.

We make it for one.

Market Opportunity → A large market that mass production cannot serve

Personalized medicine is growing. The exact dose, for one patient, is what 3D printing can make

$567B → $1.2T

Personalized-medicine market, 2024 → 2033

$141B → $295B

Peptide therapeutics market, 2025 → 2033

The Problem

Pharmaceutical manufacturing focuses on millions of identical pills.

Children, seniors, rare diseases and personalized doses are left out.

The Solution

Print the exact dose, for the specific patient, on demand, at a pharmacy near them.

Opportunity Window

Regulators are opening the door to compounded peptides and printed medicines. Telehealth is bringing patients.

New: HHS now lets 503A pharmacies compound six peptides, including KPV and BPC-157 (Oct. 2026).

Sources: Figures in USD. Grand View Research (Personalized Medicine; Peptide Therapeutics market reports); FDA PCAC, July 2026; HHS policy notice, Docket HHS-OASH-2026-0496 (Oct. 2026). Market data not independently verified by the Company.

Why 3D Printing of Medicines

Five things mass pharmaceutical production can not do economically.

	MASS PRODUCTION		3D PRINTING
Batch size	Pays off only at millions of units	→	**Economic from tens to thousands of units**
Dose	A few fixed strengths; patients split pills	→	**Any dose, ±1% accurate, from one recipe**
Pill design	One medicine, one release speed	→	**Several medicines and release speeds in one pill**
Process	Heat, pressure or UV; hard on peptides	→	**Room temperature; peptides stay intact**
Location	Central plants, often overseas	→	**Locally: a pharmacy, hospital or node**


Dose accuracy and room-temperature process per Craft Health platform specifications. Illustrative.

Our Solution


M3DICINES™ 3D-Printed Medicines Platform

Precise, room-temperature (no heat, no UV) printing of customized doses on GMP-ready CraftMake⅛

CRAFTMAKE™ 3D PRINTER



CRAFTCONTROL™ SOFTWARE




No-code dose templates · audit trail · multi-printer

DOSAGE FORMS



Pellets & mini-tablets



Dual-print tablets




Gummies & chewables



Multi-layered tablets




Liquid-embedded chewables



Liquid-core chewables



Multi-layered capsules



Oral dissolvable films

RELEASE PROFILES

- Immediate
- Sustained
- Delayed
- Colon-targeted
- Enhanced solubility
- Gastro-retentive

PATENT PORTFOLIO

Owned by Craft Health

4 patent families

3 granted · U.S. and Japan

4 pending · U.S. and U.K.

Covers: colon-targeted, long-release and poorly soluble actives

Images: Craft Health platform-capability imagery, including the CraftControl™ software photo, shared with PharmaTher under the companies' collaboration and distribution agreements. ±1% dose precision and >95% repeatability per Craft Health specifications. Patents owned by Craft Health (granted: US 12,544,310; JP 7525935; JP 7624750), status at Oct. 16, 2026; PharmaTher holds exclusive North American distribution rights.

Exclusive North American Rights to CraftMake⅛

10,000+ potential sites across North America.



CraftMake⅛

3D printing system by Craft Health

GMP-READY

ROOM TEMP · NO HEAT, NO UV

±1% PRECISION · >95% REPEATABILITY

Every placement is infrastructure, not a one-time sale.

Each system keeps earning.

Every placement can support PharmaTher and partner programs.

Telehealth, brands, R&D, and national emergencies.

POTENTIAL PARTNERS & CUSTOMERS

503A compound pharmacies
~7,500 U.S. 503A pharmacies alone

Telehealth and consumer health
White-label products and manufacturing

CDMOs, pharma and biotech
Clinical supply and production

Hospitals and health systems
Pediatric and special-population doses

Academic and research labs
Feasibility and validation studies

Government and defence
Preparedness and countermeasures

Placement estimate is a management estimate and forward-looking; nodes require site qualification. CraftMake⅛ is a Craft Health product; specifications per Craft Health.

Business Model

Our moat: exclusive CraftMake⅛ rights plus our own formulations and data, made possible only by 3D printing.

TELEHEALTH

We sell our printed peptides, direct and through partners.

Peptide gummies

Heat-free gummies, dosed to the prescription

Peptide tablets and pellets

Printed at any strength from one recipe

Colon-targeted peptides

Printed to release where the disease is

PARTNERING

We put the platform to work for others.

In-house placements

CraftMake⅛ printers in pharmacies, hospitals, labs, pharma/biotech

CDMO and white-label

We make products for partners

Business development

Strategic alliances and licensing

REVENUE STACK

- Product sales
- System placements
- Consumables & service
- Development fees
- Licences & royalties
- Government contracts
- Voucher sales
- Asset monetization

Our Programs

Peptides and Longevity

Peptides and NAD+/NMN in a gummy, dosed for one patient, with no heat and no UV.







Peptide

BPC-157 · KPV · gummy, tablet or pellet

Layered, single-dose or core-and-shell gummies, printed at 25°C with no UV, so fragile peptides stay intact.



Longevity Gummy

NAD+ and NMN in one gummy, two layers

A combination no fixed-ratio product can match, at the ratio and strength a clinician prescribes. Sold through clinicians and telehealth.

$141B → $295B

peptide therapeutics market, 2025 → 2033

$3.9B → $12.2B

NAD+ products market, 2025 → 2033

Formats shown are concepts; gummy photos are food-grade demonstration samples (layered gummy: vitalayer.shop; other images courtesy of Craft Health). 503A products are patient-specific compounded prescriptions and are not FDA-approved; BPC-157 and KPV may be compounded only as the HHS policy and FDA rulemaking allow; no efficacy claims are made. Sources: Grand View Research (Peptide Therapeutics; NAD+ Products, 2025). Timing is an internal estimate.

Colon-targeted peptides: first in line for a new U.S. peptide market

HHS opened a peptide pathway in Oct. 2026; only KPV and BPC-157 are covered for oral use.

HOW IT WORKS · A PILL-IN-PILL THAT OPENS IN THE COLON



Stomach
Shell holds in acid

Small intestine
Shell keeps holding

Colon
Peptide released where the disease is

12,000×
lower KPV dose gave a similar effect when delivered to the colon (mouse colitis study)

Up to 75%
of the dose reached a simulated colon, vs. under 10% for a commercial product (in vitro)

OUR OPPORTUNITY, OUR MOAT

A new market just opened
HHS's Oct. 2026 policy lets 503A pharmacies compound six peptides; only KPV and BPC-157 for oral use.

A clear unmet need
30–60% of ulcerative colitis patients have disease in the lower colon, which most oral budesonide products aren't designed to reach.

Hard to copy
Patent-pending CORR3CT⅛ design and exclusive North American CraftMake⅛ rights. No heat, so fragile peptides stay intact.

Ready to sell through partners
Made at PD Labs, our U.S. 503A Center of Excellence, for telehealth platforms and pharmacies with patients.

$29.6B
global IBD treatment market, 2025

$141B
peptide therapeutics market, 2025

600–900K
Americans with ulcerative colitis

Animal (mouse colitis) and in vitro (budesonide model) data; results in humans are not established. Compounded peptides are not FDA-approved; the HHS policy is interim and may be revised or applied differently by states. No efficacy claims are made. Sources: PharmaTher news release, Oct. 29, 2026; HHS policy notice (Docket HHS-OASH-2026-0496); Grand View Research; NIDDK. Market data not independently verified by the Company.

FDA program: GAMT Deficiency, a rare childhood disease with no approved treatment

3D-printed creatine; approval could earn a priority review voucher worth US$150–200M.

The disease

Children born unable to make creatine.
Untreated: disability and seizures by age three.

Today

Creatine powder, mixed by hand, 3–6 times a day, for life.
Never approved as a drug.

Our product

Printed oral pellets of creatine monohydrate in weight bands, at ± 1%.
As a child grows, the next dose is a file change.



WHAT APPROVAL CAN EARN

7 years of U.S. market exclusivity, plus an FDA fee waiver and a trial tax credit (orphan drug designation)

A voucher for a six-month FDA review of any future drug; transferable, so small companies sell them to large pharma

WHAT RARE PEDIATRIC VOUCHERS HAVE SOLD FOR · US$ MILLIONS



Sources: PharmaTher news release, Oct. 28, 2026; 21 USC 360ff; company press releases on each voucher sale. Investigational; not FDA-approved. The FDA may not grant either designation; a voucher may not be awarded or sold, and vouchers can be awarded only for approvals by Sept. 30, 2029 unless the program is extended. Timelines are internal estimates. Pellet and granule images courtesy of Craft Health.

Additional Product Opportunities

Too small for a production line, and exactly right for 3D printing.

Rare diseases

Patients may need only a few thousand doses a year, often in weight-based strengths.

~10,000
known rare diseases

~95%
have no FDA-approved treatment

FDA Rare Disease Evidence Principles (2025): for certain genetic diseases affecting fewer than 1,000 U.S. patients, approval can rest on one adequate and well-controlled study plus confirmatory evidence.

Psychedelic medicines

Precisely dosed psilocybin and MDMA, with matching placebos, for trials and access programs.




Same look and size, so trials stay blinded

Access is opening: Health Canada Special Access Program · Australia's Authorised Prescriber Scheme · a 2026 U.S. executive order directing a Right to Try pathway.

Discontinued & short-supply

Medicines dropped because demand got too small for a factory, or short because they are made far away.



Two routes back: FDA abbreviated pathways or 503A compounding, from a team that has already taken a ketamine ANDA through FDA approval.

Sources: U.S. National Institutes of Health (NCATS); U.S. FDA, Rare Disease Evidence Principles (September 2025). Psilocybin and MDMA are Schedule I controlled substances in the United States and are controlled in Canada; they are not approved by the FDA, and their manufacture, supply and use require licences and authorizations from the DEA, Health Canada and other regulators. Reintroducing a discontinued medicine depends on FDA confirmation that it was not withdrawn for safety or effectiveness reasons, or on 503A eligibility. Plans and timelines are internal estimates and forward-looking.


Telehealth Programs: Unique to our 3D printer technology

Telehealth platforms and pharmacies add a differentiated, documented peptide without building a lab.

OUR BRAND

PERSONALIZ3D℠

Telehealth site: an online visit, a printed prescription, shipped home.




personaliz3d.com (illustrative mockup)

PARTNER BRANDS

Partner telehealth

Telehealth platforms add our printed peptides under their own brand, powered by M3DICINES℠.



Fictional partner site (illustrative mockup)

Built to the rules

FDA-registered API, named-patient prescriptions, adverse-event reporting.

Oral and needle-free

Against injectable or commodity peptides; quality, not claims, carries the offer.

Made at PD Labs

Our U.S. 503A Center of Excellence, then repeated at other qualified nodes.

US$35.9B → US$156B
U.S. telemedicine market, 2025 → 2035

US$141B → US$295B
Peptide therapeutics market, 2025 → 2033

2
peptides cleared for oral use under the HHS policy

Website screens are illustrative mockups; PERSONALIZ3D℠ is shown as a concept and Northstar Health is a fictional partner. Windows are management targets. Compounded products are not FDA-approved; the HHS policy is enforcement discretion, not FDA approval, and may be revisited. Sources: Global Market Insights, U.S. Telemedicine Market (2025); Grand View Research; HHS policy notice (Oct. 30, 2026).

Partnership opportunities

Ways to work with us

Three ways in, one platform: every partner adds recurring revenue.




Bring 3D printing in-house

For pharmacies, hospitals, CDMOs and labs.

Printer, software, training and service included.

EARNS **Placements, consumables, software and service**




Let us make it

For telehealth, pharma, biotech, and government.

Feasibility studies, clinical trial supply and small-batch production through PD Labs and our GMP partner.

EARNS **Development and supply fees**



Build a product together

For telehealth, consumer-health and pharma brands.

White-label products, co-development, joint ventures, alliances and licensing of our formulations.

EARNS **Licences, royalties and product margin**

~7,500
U.S. 503A compounding pharmacies

10,000+
potential network sites in North America

Terms are subject to site qualification and definitive agreements; introductory pricing is limited to up to ten selected 503A pharmacies. Site count is a management estimate. White-label screen is an illustrative mockup with a fictional partner. Images courtesy of Craft Health.

Strategic Assets: Monetization outside the 3D printing core

Ketamine ANDA payments expected from Q1 2027. Other assets available to license, sell, partner or spin out.

Ketamine ANDA

>US$25M

potential over time: milestones plus a 7-year profit share

Sold Dec. 2025; payments expected from Q1 2027

KetaVault⅛

5

orphan designations

CMC package, INDs and protocols: a gateway for ketamine programs

Ketamine patch

40 h

extended delivery shown

Microneedle patch; Phase 1-ready

KetaMist®

9,000+

patient treatments to date

Needle-free ketamine; collaboration toward an FDA pathway

Sairiyo (49%)

US$3.5M

U.S. Defense investment (Ebola)

Patented, orally bioavailable cepharanthine

Potential ANDA payments depend on the purchaser's commercial performance and are not assured (press release, Dec. 2, 2025). Asset transactions may not occur on acceptable terms. KetaMist® is a trademark of its owner; not FDA-approved.

An asset-light model with three partners, already in place

Craft Health

TECHNOLOGY

Exclusive North American distributor

CraftMake™ systems, software, materials and service. Every placement seeds recurring revenue and runs M3DICINES™ formulations.

pdlabs
prescription dispensing laboratories

DISPENSING AND R&D

Center of Excellence

PD Labs: a U.S. national 503A compounding pharmacy with 26+ years of experience, for dispensing and R&D.

MANUFACTURING


GMP contract manufacturer

FDA-track products and CDMO services, including clinical trial supply.

Future Opportunities

Our Vision of a M3DICINES⅛Network for National Emergencies

Commercial work in peacetime. Countermeasures in an emergency.



1 · Validate and qualify

We validate the recipes; each partner installs CraftMake⅛ and is qualified and trained.

2 · Peacetime

Nodes print for patients, our products, partners and research.

3 · Emergency

We release validated recipes; qualified nodes print the doses needed, locally, in the strengths patients need.

10,000+
potential network sites (management estimate)

~26
critical drugs the U.S. API Reserve will stock as ingredients

12 mo
planned demonstration; ASPR and DRDC contracts pursued

Illustrative; node locations are not actual. Nodes require site qualification and definitive agreements; the placement estimate is internal and forward-looking. The preparedness network is planned and readiness contracts are prospective; there is no finalized FDA framework for distributed manufacturing. Sources: Executive Order 14336 (Aug. 2025); ASPR EQUIP-A-Pharma (2025).

Future Telehealth Programs

Only 3D printing can make these: any dose, any form, made for one patient.



Pediatrics

Children are dosed by weight, but medicines come in adult strengths. We print weight-banded doses in forms children accept.

15–37% of children's oral doses are altered by hand because no suitable strength exists



Dysphagia

People with Parkinson's, ALS or stroke crush, split or skip pills they cannot swallow. We convert their medicine into a form they can. This also applies to people who fear swallowing or injecting medicine.

~70% of Parkinson's patients had difficulty swallowing medication on endoscopic evaluation



Deprescribing (tapering off)

Coming off an antidepressant takes dozens of small, declining doses that tablets cannot provide. We print the whole taper ladder in one run.

13.2% of U.S. adults take an antidepressant

All reuse the formulation library, software and pharmacy network that the peptide programs build.

Future programs; timing depends on the peptide programs, partner agreements and regulatory review. Compounded products are not FDA-approved. Sources: PubMed PMID 40600756; Labeit et al., npj Parkinson's Disease 2022; CDC NCHS; PharmaTher × CHLA briefing, Oct. 2026.

Future Product Partnership Programs

Partners bring the customers and the brand; we bring the printed product.



Nutraceuticals

Vitamins and supplements in layered gummies and liquid-filled chewables, printed with no heat so probiotics and botanicals stay intact. For supplement and wellness brands.

$16B → $49B personalized nutrition supplements market, 2025 → 2033



Pet health

Pets need doses matched to their weight, in a form they will eat. We print exact-dose, flavored chewables in any shape for veterinary pharmacies and pet-health brands.

$1.7B → $3.3B animal drug compounding market, 2025 → 2033



Repurposed & reformulated

New forms of FDA-approved drugs, such as child-friendly doses, combinations or new release profiles, through the 505(b)(2) pathway the first 3D-printed medicine used in 2015.


69 FDA-approved reformulations of existing drugs in 2024–25; 41 were new dosage forms

Same printers, formulations and network; partners carry the sales and marketing.

Future programs; timing depends on partner agreements and regulatory review. Supplements and veterinary products follow their own rules; reformulated drugs need FDA approval. Sources: Grand View Research (Personalized Nutrition Supplements; Animal Drug Compounding, 2026); Pharmaceutical Technology, 505(b)(2) review (Nov. 2025). Images courtesy of Craft Health. Market data not independently verified by the Company.

Expected Milestones: the next 12 months

Product launches, commercial and partnering sales and FDA decisions.



1

From Q4 2026

PERSONALIZ3D peptide telehealth launch: BPC-157 and KPV gummies, tablets, colon-targeted; NAD+/NMN gummy

2

Q4 2026 – 2027

CraftMake⅛placements in 503A pharmacies

3

Q1 2027

FDA decisions on GAMT designations (ODD, RPD)

4

Q1 2027

First ketamine ANDA payments

5

2027

White-label and CDMO agreements

6

2027

Licensing, sale or spin-out of strategic assets

Milestones and timelines are internal targets and forward-looking statements; they may change. Compounded products are not FDA-approved. ANDA payments depend on the purchaser's commercial performance and are not assured.

Leadership across drug development, FDA approvals, compound pharmacy, commercialization, and manufacturing

MANAGEMENT & BOARD



Fabio Chianelli

Founder, Chairman & CEO

25+ years in specialty life sciences and investing; founder of PharmaTher and Revive Therapeutics.



Carmelo Marrelli

Chief Financial Officer

Public-company finance and administration; principal of Marrelli Support Services since 2009.



Dr. Beverly J. Incledon

Director

30+ years in pharma and drug delivery; former EVP R&D at Ironshore Pharmaceuticals.

CS

Carlo Sansalone

Director

Investor across biotech, technology and real estate; President at Sanscon.

PARTNER LEADERSHIP



Ray Solano

Founder & President, PD Labs

Clinical pharmacist for 35 years and certified clinical nutritionist; PD Labs is PharmaTher's U.S. 503A Center of Excellence.



Dr. Wei Jiang Goh

Co-founder & CEO, Craft Health

Pharmacist; co-founder of Craft Health, maker of CraftMake™. PhD and MBA, National University of Singapore.



Dr. Seng Han Lim

Co-founder & COO, Craft Health

Pharmacist; co-founder of Craft Health. PhD in pharmacy (NUS) focused on 3D-printed personalized dosage forms.

Capital structure

As at September 30, 2026

91,019,065

Issued and outstanding common shares

1,500,000

Stock options outstanding

~19%

Insider ownership

PHRM (CSE) **PHRRF** (OTCQB)

COMPANY FACTS

Transfer agent

Marrelli Trust Company Limited

Auditor

Truster Zweig Raithatha (TZR)

Fiscal year-end

June 30

Filings

SEDAR+ (www.sedarplus.ca)

Thank You

info@pharmather.com · 1-888-846-3171

pharmather.com